NOVEL MUCOSAL VACCINE APPROACHES FOR PNEUMONIA.

支持候选产品的高级开发，以便在故意释放传染病（包括新出现的传染病）之后使用或应对自然发生的传染病暴发。该合同可支持单个疫苗组分的配制和生产，以及动物模型中的稳定性试验、非临床免疫原性和有效性试验、IND启用GLP毒理学、IND提交以及临床安全性和有效性评价。

To support the advanced development of candidate products for use following the intentional release of or in response to naturally occurring outbreaks of infectious diseases, including emerging infectious diseases. This contract may support formulation and manufacture of the individual vaccine components, as well as stability testing, nonclinical immunogenicity and efficacy testing in animal models, IND enabling GLP toxicology, submission of an IND and clinical safety and efficacy evaluation.